Osteoporosis International

, Volume 14, Issue 10, pp 793–800 | Cite as

Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial

  • H. Morii
  • Y. Ohashi
  • Y. Taketani
  • M. Fukunaga
  • T. Nakamura
  • A. Itabashi
  • S. Sarkar
  • K. Harper
Original Article

Abstract

The safety and efficacy of raloxifene, a selective estrogen receptor modulator (SERM), has been studied extensively in large, global clinical trials. However, the effect of raloxifene on bone mineral density (BMD) and on biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis has not been rigorously evaluated. This study was designed to assess the safety and efficacy of raloxifene in Japanese postmenopausal women with osteoporosis following 1 year of therapy. Participants in this multicenter trial were randomly assigned to receive placebo, raloxifene 60 mg/day (RLX60), or raloxifene 120 mg/day (RLX120). Lumbar spine BMD was measured at baseline, 24, 40, and 52 weeks, and biochemical markers of bone turnover were assessed at baseline, 12, 24, and 52 weeks. Serum lipids were assessed at baseline, 12, 24, 40, and 52 weeks, and breast examinations and transvaginal ultrasound of the endometrium were performed at enrollment and 52 weeks. Compared with baseline, women taking RLX60 had significant increases in lumbar spine (L2-L4) BMD at 24 weeks (+3.3%, p<0.001) through 52 weeks (+3.5%, p<0.001) of therapy, and similar results were observed in the RLX120 group. Markers of bone turnover and total cholesterol and LDL-C were significantly reduced, and no significant treatment-group difference was observed for patients reporting at least one adverse event following randomization. In addition, there were no reported venous thromboembolic events (VTE) in any treatment group. The results of this study demonstrate that raloxifene is associated with early increases in lumbar spine BMD, has favorable effects on biochemical markers of bone turnover and lipid profile, and is well tolerated in postmenopausal Japanese women.

Keywords

BMD Bone markers Japanese Lipid profile Raloxifene Safety 

References

  1. 1.
    Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282:637–645PubMedGoogle Scholar
  2. 2.
    Johnston CC Jr, Bjarnason NH, Cohen FJ et al (2000) Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipipds in early postmenopausal women. 3-year data from two double-blind, randomized, placebo-controlled trials. Arch Intern Med 160:3444–3450CrossRefPubMedGoogle Scholar
  3. 3.
    Delmas PD, Ensrud KE, Adachi JD et al (2002) Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87:3609–3617Google Scholar
  4. 4.
    Walsh BW, Kuller LH, Wild RA et al (1998) Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 279:1445–1451PubMedGoogle Scholar
  5. 5.
    Barrett-Connor E, Grady D, Sashegyi A et al (2002) Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 287:847–857PubMedGoogle Scholar
  6. 6.
    Cummings S, Eckert S, Krueger K et al (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA 281:2189–2197PubMedGoogle Scholar
  7. 7.
    Cauley JA, Norton L, Lippman ME et al (2001) Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treat 65:125–134CrossRefPubMedGoogle Scholar
  8. 8.
    Cohen FJ, Watts S, Shah A et al (2000) Uterine effects of three-year raloxifene therapy in postmenopausal women younger than age 60. Obstet Gynecol 95:104–110CrossRefPubMedGoogle Scholar
  9. 9.
    Lufkin EG, Wong M, Deal C (2001) The role of selective estrogen receptor modulators in the prevention and treatment of osteoporosis. Rheum Dis Clin North Am 27:163–185PubMedGoogle Scholar
  10. 10.
    Maricic M, Adachi JD, Sarkar S et al (2002) Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med 162:1140–1143CrossRefPubMedGoogle Scholar
  11. 11.
    Cohen FJ, Lu Y (2000) Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials. Maturitas 34:65–73CrossRefPubMedGoogle Scholar
  12. 12.
    Kanis JA, Melton LJ3, Christiansen C et al (1994) The diagnosis of osteoporosis. J Bone Miner Res 9:1137–1141PubMedGoogle Scholar
  13. 13.
    Orimo H et al (1995) The criteria for the diagnosis of primary osteoporosis. The Examination Committee for the Criteria of Osteoporosis Diagnosis—the Japanese Society for Bone and Mineral Research. Osteoporos Int 3:111–116Google Scholar
  14. 14.
    Lu Y, Ye K, Mathur AK et al (1997) Comparative calibration without a gold standard. Stat Med 16:1889–1905CrossRefPubMedGoogle Scholar
  15. 15.
    Lu Y, Mathur AK, Blunt BA et al (1996) Dual X-ray absorptiometry quality control: comparison of visual examination and process-control charts. J Bone Miner Res 11:626–637PubMedGoogle Scholar
  16. 16.
    Genant HK, Jergas M, Palermo L et al (1996) Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. J Bone Miner Res 11:984–996PubMedGoogle Scholar
  17. 17.
    Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18(6):499–502PubMedGoogle Scholar
  18. 18.
    Goldstein SR, Scheele WH, Rajagopalan SK et al (2000) A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium . Obstet Gynecol 95:95–103CrossRefPubMedGoogle Scholar
  19. 19.
    Brown EG, Wood L, Wood S (1999) The medical dictionary for regulatory activities (MedDRA). Drug Saf 20:109–117PubMedGoogle Scholar
  20. 20.
    Efron B, Stein C (1981) The jackknife estimate of variance. Ann Stat 9:586–596Google Scholar
  21. 21.
    Sarkar S, Mitlak BH, Wong M et al (2002) Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17:1–10PubMedGoogle Scholar
  22. 22.
    Delmas PD, Bjarnason NH, Mitlak BH et al (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337:1641–1647PubMedGoogle Scholar
  23. 23.
    Lips P, Duong T, Oleksik A et al (2001) A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial. J Clin Endocrinol Metab 86:1212–1221Google Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2003

Authors and Affiliations

  • H. Morii
    • 1
    • 8
  • Y. Ohashi
    • 2
  • Y. Taketani
    • 3
  • M. Fukunaga
    • 4
  • T. Nakamura
    • 5
  • A. Itabashi
    • 6
  • S. Sarkar
    • 7
  • K. Harper
    • 7
  1. 1.Osaka City UniversityOsakaJapan
  2. 2.Biostatistics, School of Health Sciences and NursingUniversity of TokyoTokyoJapan
  3. 3.Department of Obstetrics and GynecologyUniversity of TokyoTokyoJapan
  4. 4.Department of Nuclear MedicineKawasaki Medical SchoolOkayamaJapan
  5. 5.Orthopedic SurgeryUniversity of Occupational and Environmental HealthKitakyushuJapan
  6. 6.Department of Clinical LaboratorySaitama Medical SchoolSaitamaJapan
  7. 7.Lilly Research LaboratoriesEli LillyIndianapolisUSA
  8. 8.2–11–25 MukoyamaTakarazuka-CityJapan

Personalised recommendations